• 1
    Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): II43II47.
  • 2
    Bommelaer G, Poynard T, Le PC et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol Clin Biol 2004; 28 (6-7 Pt 1): 55461.
  • 3
    Hungin AP, Whorwell PJ, Tack J et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003; 17: 64350.
  • 4
    Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006; 130: 148091.
  • 5
    Ford AC, Talley NJ, Spiegel BM et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313.
  • 6
    Parkes GC, Brostoff J, Whelan K et al. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 2008; 103: 155767.
    Direct Link:
  • 7
    Marshall JK, Thabane M, Garg AX et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010; 59: 60511.
  • 8
    Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 35036.
    Direct Link:
  • 9
    King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 11879.
  • 10
    Moayyedi P, Ford AC, Talley NJ et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2010; 59: 32532.
  • 11
    Silk DB, Davis A, Vulevic J et al. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 50818.
  • 12
    Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 2232.
  • 13
    Kassinen A, Krogius-Kurikka L, Makivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 2433.
  • 14
    Malinen E, Rinttila T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 37382.
    Direct Link:
  • 15
    Balsari A, Ceccarelli A, Dubini F et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5: 18594.
  • 16
    Kerckhoffs AP, Samsom M, van der Rest ME et al. Lower bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15: 288792.
  • 17
    Si JM, Yu YC, Fan YJ et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10: 18025.
  • 18
    O’Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 54151.
  • 19
    Wyatt GM, Bayliss CE, Lakey AF et al. The faecal flora of two patients with food-related irritable bowel syndrome during challenge with symptom-provoking foods. J Med Microbiol 1988; 26: 2959.
  • 20
    Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the human intestinal microbial flora. Science 2005; 308: 16358.
  • 21
    Langhorst J, Wieder A, Rueffer A et al. Activated innate immune system in irritable bowel syndrome? Gut 2007; 56: 13256.
  • 22
    Finegold S, Sutter VL, Mathisen GE. Normal indigenous intestinal flora. In: Hentges DJ, ed. Human Intestinal Flora in Health and Disease. New York: Academic Press, 1983: 331. Ref Type: Serial (Book, Monograph).
  • 23
    Sartor RB, Muehlbauer M. Microbial host interactions in IBD: implications for pathogenesis and therapy. Curr Gastroenterol Rep 2007; 9: 497507.
  • 24
    Sellon RK, Tonkonogy S, Schultz M et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66: 522431.
  • 25
    Mylonaki M, Rayment NB, Rampton DS et al. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 4817.
  • 26
    Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395402.
  • 27
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 36170.
  • 28
    Franks AH, Harmsen HJ, Raangs GC et al. Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol 1998; 64: 333645.
  • 29
    Swidsinski A, Weber J, Loening-Baucke V et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005; 43: 33809.
  • 30
    Macfarlane S, Woodmansey EJ, Macfarlane GT. Colonization of mucin by human intestinal bacteria and establishment of biofilm communities in a two-stage continuous culture system. Appl Environ Microbiol 2005; 71: 748392.
  • 31
    Gueimonde M, Ouwehand A, Huhtinen H et al. Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease. World J Gastroenterol 2007; 13: 39859.
  • 32
    McCoubrey H, Parkes GC, Sanderson JD et al. Nutritional intakes in irritable bowel syndrome. J Hum Nutr Diet 2008; 21: 3967.
  • 33
    Green GL, Brostoff J, Hudspith B et al. Molecular characterization of the bacteria adherent to human colorectal mucosa. J Appl Microbiol 2006; 100: 4609.
  • 34
    Matto J, Maunuksela L, Kajander K et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome – a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005; 43: 21322.
  • 35
    Koide A, Yamaguchi T, Odaka T et al. Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 173541.
    Direct Link:
  • 36
    Salvioli B, Serra J, Azpiroz F et al. Origin of gas retention and symptoms in patients with bloating. Gastroenterology 2005; 128: 5749.
  • 37
    Accarino A, Perez F, Azpiroz F et al. Abdominal distention results from caudo-ventral redistribution of contents. Gastroenterology 2009; 136: 154451.
  • 38
    Whorwell PJ, Altringer L, Morel J et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 158190.
    Direct Link:
  • 39
    Kajanda K, Myllyluoma E, Rajilic-Stojanovic M et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008; 27: 4857.
  • 40
    Enck P, Zimmermann K, Menke G et al. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome – a randomized controlled trial with primary care physicians. Neurogastroenterol Motil 2008; 20: 11039.
  • 41
    Mueller S, Saunier K, Hanisch C et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol 2006; 72: 102733.
  • 42
    Amann RI, Binder BJ, Olson RJ et al. Combination of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analyzing mixed microbial populations. Appl Environ Microbiol 1990; 56: 191925.
  • 43
    Langendijk PS, Schut F, Jansen GJ et al. Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus-specific 16S rRNA-targeted probes and its application in fecal samples. Appl Environ Microbiol 1995; 61: 306975.
  • 44
    Manz W, Amann R, Ludwig W et al. Application of a suite of 16S rRNA-specific oligonucleotide probes designed to investigate bacteria of the phylum cytophaga-flavobacter-bacteroides in the natural environment. Microbiology 1996; 5: 1097106.
  • 45
    Harmsen HJM, Elfferich P, Schut F et al. A 16S rRNA-targeted probe for detection of lactobacilli and enterococci in faecal samples by fluorescent in situ hybridization. Microb Ecol Health Dis 1999; 11: 312.
  • 46
    Poulsen LK, Licht TR, Rang C et al. Physiological state of Escherichia coli BJ4 growing in the large intestines of streptomycin-treated mice. J Bacteriol 1995; 177: 58405.